Pharmanumbers Home
Whats New:
January 1, 2012
Year End Index Update
Latest Article
Pharma Revolution Recalibrated, Pharmaceutical Executive, November 2011
Latest Blog Entry
Bionumbers Index
January 1, 2012
All Indexes Updated - Year End 2011
November erased the gains of October for the DDI and ESPI, both down 4.9% for the month. On the flip side, November was a good month for the CSPI which was up 4.9%, and is up 15.9% for the year.
DDEP2011 Report
Updated - September 2011
Our DDEP2011 report focuses on Drug Delivery and goes far beyond a simple listing and analysis of product sales. DDEP 2011 analyzes a wide variety of development and commercialization parameters that impact product success. The development parameters include: clinical development times, phase transition rates, success rates, and development costs. Commercialization parameters include: sales and prescriptions, market exclusivity and sales uptake curves. More information on DDEP2011 is available.
Welcome to The Pharmanumbers Goup
We are Drug Delivery specialists with a focus on understanding new products and markets to ensure an optimal fit. Our services range from consulting and resource help (Pharmanumbers), to industry analysis and reports (Bionumbers).
Pharmanumbers
Pharmanumbers provides companies with consulting and resource help. Our clients cover the full spectrum of biopharma companies, from start-ups to companies that are commercially successful and profitable. We provide hands on support and resources in the areas of business and corporate development, with a focus on new product planning, sales and profitability forecasting, as well as deal term development and evaluation.
Bionumbers
Bionumbers prepares industry analyses and reports that go beyond the expected to uncover the key parameters and factors impacting product development success and prfitability. Our most recent report DDEP2011, analyzes the Drug Delivery business from the perspective of pipeline success rates, clinical development times and a number of commercial sucess parameters such as sales, prescriptions, and market exclusivity periods. These are the numbers that companies and investors need to understand if they hope to develop profitable new products that meet budgets and timelines.
Looking for the Bionumbers Market Cap Index? You can find it at the Bionumbers Index tab.
